Membrane APRIL CHO Cell Line

The Membrane APRIL CHO Cell Line is a clonal CHO cell line stably expressing an engineered, cleavage-resistant form of APRIL (A proliferation-inducing ligand), that enforces its cell surface localization. This cell line has been validated by flow cytometry, and in a co-culture assay with BAFF/APRIL Responsive BCMA-NF-kappaB Luciferase Reporter HEK293 Cell Line (#79755) in the presence of Sibeprenlimab. APRIL (A proliferation-inducing ligand), also known as TNSF13 or CD256, activates a signaling pathway that participates in the regulation of B-cell development, autoimmunity, and long-term plasma cell survival. This protein is a member of the tumor necrosis factor (TNF) ligand family and a ligand for BCMA/ TNFRSF17. APRIL expression is significantly elevated in multiple myeloma (MM), and it has been demonstrated that activation of BCMA by APRIL promotes tumor growth, chemoresistance, and immunosuppression in the bone marrow microenvironment. Anti-APRIL monoclonal antibodies, such as sibeprenlimab and zigakibart, have recently progressed to clinical trials for Immunoglobulin A Nephropathy (IgAN) and MM, respectively. Macrophages express a membrane-bound form of APRIL, which may be involved in immunomodulation. The study of membrane-bound APRIL may be of relevance for the treatment of inflammatory disorders.